奥拉西坦减轻抗炎活性并改善创伤性脑损伤早期认知障碍
本研究通过体外损伤SH-SY5Y细胞(奥拉西坦100 nM)和体内C57BL/6 J小鼠创伤性脑损伤模型(腹腔注射奥拉西坦30 mg/kg/day,共5天),发现奥拉西坦可降低COX-2、NLRP3、caspase-1和IL-1β表达,减少脑水肿和细胞凋亡,并改善认知功能。
要点
- 体外实验显示奥拉西坦100 nM可增加SOD1和SOD2 mRNA表达,降低COX-2、NLRP3、caspase-1和IL-1β表达。
- 体内实验显示奥拉西坦30 mg/kg/day腹腔注射5天可减少TBI小鼠皮质损伤、脑水肿及FJB和TUNEL阳性细胞。
- 奥拉西坦治疗组TBI小鼠认知功能改善,偏好性下降更小、潜伏期更长。
核心结论
- 奥拉西坦可能通过减轻神经炎症来帮助恢复TBI早期的认知障碍。
研究设计与样本
- 体外研究使用细胞损伤控制器损伤SH-SY5Y细胞,评估奥拉西坦100 nM的效果。
- 体内研究使用立体定位撞击器在C57BL/6 J小鼠中诱导TBI模型,腹腔注射奥拉西坦30 mg/kg/day共5天,分析免疫组化变化和认知功能。
- 研究共使用60只小鼠,分为假手术组、TBI组和TBI加奥拉西坦治疗组,每组20只。
主要发现
- 体外研究显示奥拉西坦治疗增加SOD1和SOD2 mRNA表达。
- 奥拉西坦治疗后COX-2、NLRP3、caspase-1和IL-1β的mRNA和蛋白表达降低,同时细胞内活性氧产生和凋亡效应减少。
- 与未接受奥拉西坦治疗的TBI小鼠相比,接受奥拉西坦治疗的TBI小鼠皮质损伤病灶更少、脑水肿更轻,FJB阳性和TUNEL阳性细胞更少。
- 奥拉西坦治疗后COX-2、NLRP3、caspase-1和IL-1β的mRNA和蛋白表达显著降低,这些与Iba-1阳性或GFAP阳性细胞共定位的炎症相关标志物也减少。
- 接受奥拉西坦治疗的TBI小鼠偏好性下降更小、潜伏期更长,提示认知障碍改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to investigate the effects of oxiracetam on cognitive impairment in the early phase of traumatic brain injury (TBI), for which no specific treatment is currently available. METHODS: The in vitro study used a cell injury controller to damage SH-SY5Y cells and evaluate the effect of oxiracetam at a dosage of 100 nM. The in vivo study used a stereotaxic impactor to induce a TBI model in C57BL/6 J mice and analyzed immunohistochemical changes and cognitive function after an intraperitoneal injection of oxiracetam (30 mg/kg/day) for 5 days. The number of mice used in this study was 60. They were divided into three groups (sham, TBI, and TBI with oxiracetam treatment) (20 mice in each group). RESULTS: The in vitro study showed that oxiracetam treatment resulted in increased superoxide dismutase (SOD)1 and SOD2 mRNA expression. The mRNA and protein expression of COX-2, NLRP3, caspase-1, and interleukin (IL)-1 β were decreased after oxiracetam treatment, along with decreases in intracellular reactive oxygen species production and apoptotic effects. TBI mice treated with oxiracetam exhibited the loss of fewer cortical damaged lesions, less brain edema, and fewer Fluoro-Jade B (FJB)-positive and terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL)-positive cells compared to those without oxiracetam treatment. The mRNA and protein expression of COX-2, NLRP3, caspase-1, and IL-1β were decreased significantly after oxiracetam treatment. These inflammation-related markers, which colocalized with Iba-1-positive or GFAP-positive cells after TBI, were also decreased after oxiracetam treatment. TBI mice treated with oxiracetam had a smaller decrease in preference and more latency time than those not treated with oxiracetam, suggesting the amelioration of impaired cognitive impairment. CONCLUSIONS: Oxiracetam may be helpful in restoring cognitive impairment by ameliorating neuroinflammation in the early phase of TBI.
引用
- Youn DH, Han SW, Kim JT, et al. Oxiracetam alleviates anti-inflammatory activity and ameliorates cognitive impairment in the early phase of traumatic brain injury. Acta Neurochir (Wien). 2023. PMID: 37380907. doi:10.1007/s00701-023-05674-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。